Acrylamides

Biocompatible Materials Market to Reach US$ 347 Bn by 2030; COVID-19 Restrictions to Moderately Affect Growth Prospects in Near Term - Persistence Market Research

Retrieved on: 
Friday, January 22, 2021
Biomolecules, Acrylamides, Monomers, N-(2-Hydroxypropyl) methacrylamide, Biomaterial, Chemistry, Natural sciences

Hence, increasing investments by companies for advanced product development that are non-toxic and non-immunogenic are also expected to create growth opportunities for the biocompatible materials market .

Key Points: 
  • Hence, increasing investments by companies for advanced product development that are non-toxic and non-immunogenic are also expected to create growth opportunities for the biocompatible materials market .
  • According to a latest report published by PERSISTENCE MARKET RESEARCH, the global biocompatible materials market is anticipated to experience a CAGR of over 9% during the forecast period (2020 2030).
  • The synthetic polymers segment, under material type, is expected to hold significant revenue share in the biocompatible materials market.
  • In terms of regional growth, North America, Europe, and Asia Pacific are manufacturing hubs for biocompatible materials, and are anticipated to witness rapid growth in the global biocompatible materials market.

IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (WM)

Retrieved on: 
Wednesday, December 23, 2020
Clinical medicine, Medicine, Health sciences, Orphan drugs, Breakthrough therapy, Acrylamides, Ibrutinib, Pyrazolopyrimidines, Pharmacyclics, Placebo, Graft-versus-host disease

First approved in 2013, IMBRUVICA is currently available to patients with several types of blood cancer, as well as chronic graft-versus-host disease.

Key Points: 
  • First approved in 2013, IMBRUVICA is currently available to patients with several types of blood cancer, as well as chronic graft-versus-host disease.
  • The IMBRUVICA Prescribing Information now includes final analysis data, with an overall follow-up of 63 months, from the Phase 3iNNOVATEclinical trial.
  • iNNOVATE (PCYC-1127) is a Pharmacyclics-sponsored, randomized, placebo-controlled, double-blind, Phase 3 study, which enrolled 150 patients with relapsed/refractory and treatment-nave Waldenstrm's macroglobulinemia.
  • Second primary cancers.New cancers have happened during treatment with IMBRUVICA, including cancers of the skin or other organs.

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

Retrieved on: 
Monday, December 21, 2020
Other Health, Research, General Health, Pharmaceutical, Oncology, Clinical trials, Science, Surgery, Cardiology, FDA, Other Science, Health, Lung cancer, Breakthrough therapy, Organic compounds, Chemical compounds, Health sciences, Acrylamides, Ethers, Osimertinib, Pyrimidines, Non-small-cell lung carcinoma, T790M, Other Health, Research, General Health, Pharmaceutical, Oncology, Clinical trials, Science, Surgery, Cardiology, FDA, Other Science, Health, Lung cancer, Breakthrough therapy, Organic compounds, Chemical compounds, Health sciences, Acrylamides, Ethers, Osimertinib, Pyrimidines, Non-small-cell lung carcinoma, T790M, ADAURA, TAGRISSO

TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L858R mutations as detected by an approved test.

Key Points: 
  • TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L858R mutations as detected by an approved test.
  • We remain committed to treating cancer patients earlier, when they may still have a chance of being cured.
  • TAGRISSO was recently granted Breakthrough Therapy Designation for patients in the early-stage disease setting by the US FDA.
  • In China, TAGRISSO is under priority review for the adjuvant treatment of patients with early-stage EGFRm NSCLC based on the ADAURA Phase III trial.

Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Retrieved on: 
Monday, December 7, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Cancer, Chemical compounds, Breakthrough therapy, Orphan drugs, Acrylamides, Ibrutinib, Non-Hodgkin lymphoma, Hodgkin lymphoma, Lymphoma, Follicular, Marginal Zone and Mantle Cell Lymphomas, CITADEL, Parsaclisib, Incyte

Presentations are available on the ASH website at https://www.hematology.org/meetings/annual-meeting ; #338 (Oral presentation, CITADEL-204), #2935 (Poster, CITADEL-203), #1121 (Poster, CITADEL-205), #2044 (Poster, CITADEL-205).

Key Points: 
  • Presentations are available on the ASH website at https://www.hematology.org/meetings/annual-meeting ; #338 (Oral presentation, CITADEL-204), #2935 (Poster, CITADEL-203), #1121 (Poster, CITADEL-205), #2044 (Poster, CITADEL-205).
  • Non-Hodgkin lymphoma (NHL) is a type of cancer that starts in the lymphocytes, a type of white blood cell.
  • There is an unmet medical need for treatment options for patients who are relapsed or refractory to initial therapies.
  • Patients with prior ibrutinib treatment were initially allowed to enroll; however, the cohort was terminated due to slow enrollment.

Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting

Retrieved on: 
Monday, December 7, 2020
Health sciences, Health, Orphan drugs, Chemical compounds, Breakthrough therapy, Tyrosine kinase inhibitors, Acrylamides, Ibrutinib, Pyrazolopyrimidines, Clinical trial

The data were presented at the American Society of Hematology (ASH) 2020 Virtual Annual Meeting, and a copy of the poster presentation is available online at www.oncternal.com :

Key Points: 
  • The data were presented at the American Society of Hematology (ASH) 2020 Virtual Annual Meeting, and a copy of the poster presentation is available online at www.oncternal.com :
    Session Title: 623.
  • We are in active dialogue with FDA on pivotal study design in order to define the path to approval in MCL.
  • The combination of cirmtuzumab plus ibrutinib has been well tolerated, with adverse events consistent with those reported for ibrutinib alone.
  • The CIRLL clinical trial (CIRM-0001) is a Phase 1/2 trial evaluating cirmtuzumab in combination with ibrutinib in separate groups of patients with CLL or MCL.

ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 7, 2020
Health, Other Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Chemical compounds, Drugs, Organic compounds, Acrylamides, Breakthrough therapy, Ibrutinib, Piperidines, Pyrazolopyrimidines, Camidanlumab tesirine, Loncastuximab Tesirine (Lonca), Camidanlumab Tesirine (Cami), ADC Therapeutics

Updated interim data for patients receiving the 60 g/kg Phase 2 dose of Lonca every three weeks and ibrutinib 560 mg/day were presented in a poster at ASH 2020.

Key Points: 
  • Updated interim data for patients receiving the 60 g/kg Phase 2 dose of Lonca every three weeks and ibrutinib 560 mg/day were presented in a poster at ASH 2020.
  • As of the data cut-off date of August 20, 2020, 37 patients had received the Phase 2 dose and 35 were evaluable for efficacy.
  • ADC Therapeutics anticipates reporting interim results from the pivotal Phase 2 trial of Cami in HL in the first half of 2021.
  • A live webcast of the presentation will be available on the Investors section of the ADC Therapeutics website at www.adctherapeutics.com .

New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia

Retrieved on: 
Sunday, December 6, 2020
Chemical compounds, Organic compounds, Tyrosine kinase inhibitors, Tyrosine kinases, Acrylamides, Breakthrough therapy, Ibrutinib, Pyrazolopyrimidines, Bruton's tyrosine kinase, Branches of biology, Leukemia

Continued approval for MCL and MZL may be contingent upon verification and description of clinical benefit in confirmatory trials.

Key Points: 
  • Continued approval for MCL and MZL may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • Manage cardiac arrhythmias appropriately, and if it persists, consider the risks and benefits of IMBRUVICA treatment and follow dose modification guidelines.
  • Monitor blood pressure in patients treated with IMBRUVICA and initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA as appropriate.
  • The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

TAGRISSO Granted Priority Review in the US for the Adjuvant Treatment of Patients With Early-stage EGFR-mutated Lung Cancer

Retrieved on: 
Tuesday, October 20, 2020
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Organic compounds, RTT, Chemical compounds, Lung cancer, Ethers, Acrylamides, Breakthrough therapy, Osimertinib, Clinical medicine, Pneumonitis, Cardiomyopathy, QT interval

Interstitial lung disease (ILD)/pneumonitis occurred in patients treated with TAGRISSO, some of which were fatal.

Key Points: 
  • Interstitial lung disease (ILD)/pneumonitis occurred in patients treated with TAGRISSO, some of which were fatal.
  • Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia
    Cardiomyopathy occurred in TAGRISSO-treated patients, some of which were fatal.
  • Monitor patients with cardiac risk factors and assess left ventricular ejection fraction in patients who develop symptoms during treatment.
  • EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples.

Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)

Retrieved on: 
Monday, September 7, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Breakthrough therapy, Orphan drugs, Acrylamides, Ibrutinib, Janssen Pharmaceutica, Johnson & Johnson, Cilag, Chemotherapy, Therapy, Takeda Oncology, Mantle cell lymphoma

This new non-chemotherapy combination regimen can offer extended remission, as well as fewer chemotherapy-related side effects for patients living with CLL.

Key Points: 
  • This new non-chemotherapy combination regimen can offer extended remission, as well as fewer chemotherapy-related side effects for patients living with CLL.
  • This announcement comes after the U.S. Food and Drug Administrations (FDA) approval of this expanded indication for ibrutinib in April 2020.
  • Patients are often prescribed multiple lines of therapy as they relapse or become resistant to treatments.
  • Janssen-Cilag and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Curis Reports Second Quarter 2020 Financial Results

Retrieved on: 
Tuesday, August 4, 2020
Chemical compounds, Organic compounds, Acrylamides, Breakthrough therapy, Ibrutinib, Piperidines, Pyrazolopyrimidines, Drugs, Bruton's tyrosine kinase

LEXINGTON, Mass., Aug. 4, 2020 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.

Key Points: 
  • LEXINGTON, Mass., Aug. 4, 2020 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.
  • Today, Curis announced that it will initiate a Phase 1 study evaluating CA-4948 in combination with ibrutinib, a BTK inhibitor, in the second half of 2020.
  • Curis expects to initiate a Phase 1a/1b study of CI-8993 in patients with relapsed / refractory solid tumors in the second half of 2020.
  • Revenues for the second quarter of 2020 were $2.4 million, as compared to $2.1 million for the same period in 2019.